Hannah Timmins

Current Appointments

Clinical Research Manager and Principal Research Scientist

Key Research Areas

Motor Neurone Disease and Frontotemporal Dementia

Motor neurone disease

Frontotemporal dementia

Dementia

email hidden; JavaScript is required

02 9399 1071

Dr Hannah Timmins is a Clinical Research Manager and Research Scientist with a specialised focus on neurodegenerative diseases and neurophysiological assessments. She holds a PhD in Medicine from the University of Sydney, with her work spanning critical areas including Neuropathy, Motor Neurone Disease (MND), and Frontotemporal Dementia (FTD).

In her current role, Dr Timmins oversees large-scale, cross-institutional research programs, including the coordination of international clinical trials and collaborative research efforts, where she ensures rigorous scientific execution and operational efficiency. She plays a pivotal role in strategic research planning and the overall management of clinical research operations.

As a contributor to the advancement of neurodegenerative disease research, Dr Timmins’ current work centres on improving clinical outcomes for individuals affected by MND and other neurodegenerative diseases. She is dedicated to exploring novel diagnostic tools, biomarkers and treatment strategies that aim to slow disease progression and enhance quality of life.

Support this research

Publications

2025, 15 Apr

Comparison of nab-paclitaxel, paclitaxel, and oxaliplatin-induced peripheral neuro-pathy: a cross-sectional cohort study.

View full journal-article on https://doi.org/10.2340/1651-226X.2025.42935

2025, 19 Feb

Impact of the COVID-19 pandemic on the mental and physical wellbeing of patients with motor neuron disease and other neuromuscular disease.

View full journal-article on https://europepmc.org/articles/PMC11879790

2025, 07 Feb

Utility of the Gold Coast criteria for amyotrophic lateral sclerosis: Experience with fast progressors.

View full journal-article on https://doi.org/10.1016/j.jns.2025.123417

2024 Sep

Regional health priorities for dementia: a roadmap for the Western Pacific

View full journal-article on https://doi.org/10.1016/j.lanwpc.2024.101179

2024, 01 Aug

Validity of Patient-Reported Outcome Measures in Evaluating Nerve Damage Following Chemotherapy.

View full journal-article on https://europepmc.org/articles/PMC11316238

2024, 22 Jul

Diagnostic criteria for amyotrophic lateral sclerosis.

View full journal-article on https://doi.org/10.1097/WCO.0000000000001302

2024 Jul

Novel approaches to assessing upper motor neuron dysfunction in motor neuron disease/amyotrophic lateral sclerosis: IFCN handbook chapter

View full journal-article on https://doi.org/10.1016/j.clinph.2024.04.010

2024 Apr

Plasma Lipidomic Profiling Identifies Elevated Triglycerides as Potential Risk Factor in Chemotherapy-Induced Peripheral Neuropathy

View full journal-article on https://doi.org/10.1200/PO.23.00690

2024, 15 Feb

Impact of Pain on Symptom Burden in Chemotherapy-Induced Peripheral Neurotoxicity.

View full journal-article on https://doi.org/10.6004/jnccn.2023.7083

2023, 24 May

Cortical hyperexcitability in amyotrophic lateral sclerosis: from pathogenesis to diagnosis.

View full journal-article on https://doi.org/10.1097/WCO.0000000000001162

View all publications

Donate to us

Every dollar of community support enables our scientists to continue making life-changing discoveries that contribute to a brighter and healthier future.

Learn More